Gastric metastasis from ovarian carcinoma revealed by a gastro-splenic perforation;Métastase gastrique d'un carcinome ovarien révé lée par une perforation gastro-splénique

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 5, 2004, Pages 490-493

  Dupuychaffray, Jean Pierre ^a,g   Auger, Christine ^b   Funes De La Vega, Mathilde ^c   Riche, Agnès ^d   Boulanger, Vincent ^e   Blanchot, Philippe ^f  

^a Service de Gastroentérologie   (France)

^b Service de radiologie   (France)

^c Medical and Surgical Intensive Care Unit   (France)

^d France   (France)

^e CHG Angoulême   (France)

^f CHG Angoulême   (France)

^g Centre Hospitalier d'Angouleme   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

AGED; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; METASTASIS; OVARY CARCINOMA; RARE DISEASE; SPLEEN ABSCESS; SPLEEN DISEASE; STOMACH CANCER; STOMACH PERFORATION;

EID: 3042680013     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)94969-x     Document Type: Article

References (30)

1. Caramella E, Bruneton JN, Roux P, Aubanel D, Lecomte P. Metastases of the digestive tract. Report of 77 cases and review of the literature. Eur J Radiol 1983;3:331-8.
2. Menuck LS, Amberg JR. Metastatic disease involving the stomach. Am J Dig Dis 1975;20:903-13.
3. Green LK. Hematogenous metastases to the stomach. A review of 67 cases. Cancer 1990;65:1596-600.
4. Bognel C, Lasser P, Zimmermann P. Les métastases gastriques. A propos de 17 observations. Ann Chir 1992;46:436-41.
5. Niederau C, Sobin LH. Secondary tumours of the stomach. In: Hamilton SR, Aaltoven LA? EDS. Pathology and genetics of tumours of the Digestive System. Lyon: IARS Press 2000;66-7.
6. Majerus B, Timmermans M. Gastric metastases of ovarian adenocarcinoma. A propos of a case. Acta Chir Belg 1990;90:166-71.
7. Taylor RR, Phillips WS, O'Connor DM, Harrison CR. Unusual intramural gastric metastasis of recurrent epithelial ovarian carcinoma. Gynecol Oncol 1994;55:152-5.
8. Spencer JA, Crosse BA, Mannion RA, Sen KK, Perren TJ, Chapman AH. Gastroduodenal obstruction from ovarian cancer: imaging features and clinical outcome. Clin Radiol 2000;55:264-72.
9. Fujiwara K, Ohishi Y, Koike H, Sawada S, Moriya T, Kohno I. Clinical implications of metastases to the ovary. Gynecol Oncol 1995;59:124-8.
10. Sandler RS, Sartor RB, Bozymski EM. Endoscopic appearance of cancer metastatic to the stomach. J Clin Gastroenterol 1981;3 Suppl 1:35-7.
11. Rustin GJ. The clinical value of tumour markers in the management of ovarian cancer. Ann Clin Biochem 1996;33:284-9.
12. Leroy X, Copin MC, Boman F, Gosselin B. Les cytokératines 7 et 20: aide au typage des tumeurs. Ann Pathol 1998;18:103-9.
13. Schaafsma HE, Ramaekers FC. Cytokeratin subtyping in normal and neoplastic epithelium: basic principles and diagnostic applications. Pathol Annu 1994;29:21-62.
14. Nagle RB. A review of intermediate filament biology and their use in pathologic diagnosis. Mol Biol Rep 1994;19:3-21.
15. Moll R, Lowe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
16. Wauters CC, Smedts F, Gerrits LG, Bosman FT, Ramaekers FC. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995;26:852-5.
17. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-7.
18. Park SY, Kim HS, Hong EK, Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol 2002;33:1078-85.
19. Majima T, Ichikura T, Takayama E, Chochi K, Mochizuki H. Detecting circulating cancer cells using reverse transcriptase-polymerase chain reaction for cytokeratin mRNA in peripheral blood from patients with gastric cancer. Jpn J Clin Oncol 2000;30:499-503.
20. Duval JV, Savas L, Banner BF. Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder. Arch Pathol Lab Med 2000;124:1196-200.
21. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002;117:944-51.
22. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999;85:171-7.
23. Zhou Q, Toivola DM, Feng N, Greenberg HB, Franke WW, Omary MB. Keratin 20 helps maintain intermediate filament organization in intestinal epithelia. Mol Biol Cell 2003;14:2959-71.
24. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992;44:207-12.
25. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-4.
26. Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-9.
27. Nakata B, Hirakawa-YS CK, Kato Y, Yamashita Y, Maeda K, Onoda N, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 1998;83:2488-92.
28. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
29. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol 1991;40:103-6.
30. Topuz E, Kaytan E, Saip P, Eralp Y, Sommezoglu K, Aydiner A. Comparative evaluation of diagnosing recurrent ovarian carcinoma with CA 125, PET and CT (abstract). American society of Clinical Oncology 2003:1913.